Bcr-Abl

Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: …

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to …

N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, …

Lyn-IN-1 is a selective and potent dual inhibitor of Bcr-Abl and Lyn

Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

Dasatinib is a potent inhibitor of the Bcr-Abl and Src family (IC50s: 0.6, 0.8, 79 …

Imatinib mesylate is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 …

LXH254 is a potent C-Raf and B-Raf inhibitor.

Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, …

MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of …

CGP77675 is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 …

Nilotinib hydrochloride, the hydrochloride salt form of nilotinib, is an orally bioavailable Bcr-Abl tyrosine kinase …

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 …

Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 …

MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus …

AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM …

Dasatinib hydrochloride (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor …

ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 …

CHMFL-ABL-121 is a highly potent inhibitor of type II ABL kinase (IC50s: 2 nM and …

CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: …

SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of …

BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the …

Ponatinib is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, …

AG-1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).

URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and …

Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a …

PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for …

Gypsogenin is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.

AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain …

DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, …

BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase …

CEP-32496 is a highly potent inhibitor of BRAF.

Multi-kinase inhibitor I is a Multi-kinase inhibitor.

XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM …

Bafetinib (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no …

AT9283 is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora …

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, …

ZM 306416, a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).

Berbamine dihydrochloride, a natural compound derived from the Berberis amurensis plant, has been shown to …

Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance …

AST 487 is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. …

SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, …

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes …

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates …

Asciminib (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5-0.8nM).

Degrasyn (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits …

GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 …

Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.

CZC-8004 is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.

Vodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with …

Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the …

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).

GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It …

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.

BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of …

GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: …

GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 …

Nilotinib monohydrochloride monohydrate is significantly potent BCR-ABL against, is a second generation tyrosine kinase inhibitor …

Adaphostin is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.

PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR …